Investor Presentaiton

Investor presentation First three months of 2017 Slide 48 Solid market leadership position in Japan & Korea Japan & Korea insulin market by segments Device penetration - tMU 16 14 12 10 8 6 CAGR value¹: (2.0%) MI and NGI penetration CAGR volume¹: 0.3% Penetration 100% 70% 60% 80% Fast-acting 50% 60% 40% Premix 40% 30% 20% 4 Long-acting 20% 20 10% 0% 0% Feb 2012 1 CAGR for 5-year period MI: Modern insulin; NGI: New-generation insulin Source: IMS Monthly MAT February, 2017 volume and value (DKK) figures Feb 2017 changing diabetes® Novo Nordisk Japan & Korea MI and NGI volume shares Eli Lilly Sanofi Feb 2012 Source: IMS Monthly MAT February, 2017 volume figures MI: Modern insulin; NGI: New-generation insulin Feb 2017 49% 26% 26% novo nordisk

View entire presentation